Dyne Therapeutics (NASDAQ:DYN) Receives “Buy” Rating from Chardan Capital

Chardan Capital restated their buy rating on shares of Dyne Therapeutics (NASDAQ:DYN) in a research note released on Friday morning,Benzinga reports. Chardan Capital currently has a $50.00 price target on the stock.

Several other equities analysts also recently issued reports on DYN. Guggenheim reissued a “buy” rating on shares of Dyne Therapeutics in a report on Friday, January 24th. Piper Sandler reduced their target price on shares of Dyne Therapeutics from $53.00 to $48.00 and set an “overweight” rating for the company in a research note on Friday. HC Wainwright dropped their price target on shares of Dyne Therapeutics from $55.00 to $46.00 and set a “buy” rating on the stock in a research note on Friday. Raymond James upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. Finally, Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a research report on Thursday, December 12th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, ten have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $48.64.

Dyne Therapeutics Stock Up 3.3 %

Shares of NASDAQ:DYN opened at $13.61 on Friday. The firm has a 50-day simple moving average of $16.98 and a 200 day simple moving average of $27.73. Dyne Therapeutics has a fifty-two week low of $12.87 and a fifty-two week high of $47.45. The company has a market cap of $1.39 billion, a PE ratio of -3.82 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. As a group, research analysts forecast that Dyne Therapeutics will post -3.44 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of Dyne Therapeutics stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $13.95, for a total value of $36,242.10. Following the transaction, the insider now directly owns 199,087 shares in the company, valued at $2,777,263.65. The trade was a 1.29 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Richard William Scalzo sold 1,455 shares of the company’s stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $28.12, for a total value of $40,914.60. Following the sale, the senior vice president now directly owns 127,078 shares of the company’s stock, valued at approximately $3,573,433.36. This represents a 1.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 6,387 shares of company stock valued at $142,789. Corporate insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics in the 4th quarter worth approximately $50,000. Neo Ivy Capital Management purchased a new stake in shares of Dyne Therapeutics in the fourth quarter valued at $205,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Dyne Therapeutics by 6.7% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 143,363 shares of the company’s stock worth $3,378,000 after buying an additional 9,029 shares during the period. Voloridge Investment Management LLC purchased a new position in shares of Dyne Therapeutics during the fourth quarter valued at $2,804,000. Finally, Two Sigma Advisers LP raised its position in Dyne Therapeutics by 25.4% during the fourth quarter. Two Sigma Advisers LP now owns 76,100 shares of the company’s stock valued at $1,793,000 after buying an additional 15,400 shares during the period. 96.68% of the stock is owned by hedge funds and other institutional investors.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.